Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (November 2019)
20 slides from Resonance Health's investor presentation, Nov 25, 2019
Slide 1: Investor Presentation November 2019
For personal use only INVESTOR PRESENTATION Resonance Health (ASX: RHT) is an Australian healthcare company NOVEMBER 2019 specialising in the development and delivery of non-invasive medical imaging software and analysis services.
Slide 2: Resonance Health Limited (ASX: RHT)
2 ANNUAL REPORT TEMPLATE MINIMAL DESIGN 2016/2107 For personal use only Resonance Health Limited (ASX: RHT)
Slide 3: Disclaimer
INVESTOR PRESENTATION NOVEMBER 2019 3 DISCLAIMER For personal use only This presentation has been prepared by Resonance Health Limited and may contain forward-looking statements that are based on management’s current expectations and beliefs that are subject to a number of factors and uncertainties
Slide 4: Corporate Profile
4 NOVEMBER ANNUAL REPORT 2019 TEMPLATE INVESTOR PRESENTATION MINIMAL DESIGN 2016/2107 CORPORATE For personal use only PROFILE Resonance Health is an Resonance Health has established a global Australian healthcare company distribution network of over 490 hospital specialising in the development centr
Slide 5: Corporate Structure
INVESTOR PRESENTATION NOVEMBER 2019 5 CORPORATE For personal use only STRUCTURE Board & Management • Dr Martin Blake - Non-executive Chairman • Mr Simon Panton - Non-executive Director • Dr Travis Baroni - Non-executive Director • Mr Mitchell Wells - Non-executive Director • Ms Alison Laws - Chief E
Slide 6: Recent Company Performance
66 NOVEMBER ANNUAL REPORT 2019 TEMPLATE INVESTOR PRESENTATION MINIMAL DESIGN 2016/2107 RECENT COMPANY PERFORMANCE For personal use only 52 Week Range: (0.024 - 0.17) Share Price Time (years)
Slide 7: Software as a Service (SaaS) business model
INVESTOR PRESENTATION MINIMAL DESIGN 2016/2107 ANNUAL REPORT NOVEMBER 2019 TEMPLATE 77 Software as a Service For personal use only (SaaS) business model The Resonance Health business model is to provide Software as a Service (SaaS). Under SaaS, the customer pays for service on a pay-per-use basis, r
Slide 8: FY19 Results
8 ANNUAL NOVEMBER REPORT 2019 TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 FY 19 RESULTS For personal use only $3.66M $1.15M* REVENUE EBITDA $3.08M CASH $1.27M* BALANCE NPAT • Revenue for the FY 18/19 was $3.66m, an increase of 25% versus the previous year. • Cash on hand at 30 June 2019
Slide 9: Full Year Results Comparison
MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 ANNUAL REPORT NOVEMBER 2019 TEMPLATE 9 For personal use only Column graph showing Full Year Results Comparison )000($ $)000(
Slide 10: Global Access to Services
10 10 ANNUAL REPORT NOVEMBER 2019 TEMPLATE MINIMAL INVESTORDESIGN 2016/2107 PRESENTATION GLOBAL ACCESS TO SERVICES For personal use only map icons indicate just some of our service locations, with over 490 sites having now been activated
Slide 11: Corporate Growth Through Product Innovation
MINIMAL DESIGNINVESTOR 2016/2107 PRESENTATION NOVEMBER 2019 ANNUAL REPORT TEMPLATE 11 11 CORPORATE GROWTH THROUGH PRODUCT INNOVATION For personal use only Product Improvements Significant progress has been made on the Dragon 2 study. This trial is investigating the shortening of the FerriScan® proto
Slide 12: Strong R&D Pipeline
12 NOVEMBER 2019 INVESTOR PRESENTATION STRONG R&D PIPELINE For personal use only The Company’s overall diversification strategy extends to R&D, which has 3 areas of focus: AI, imaging, and molecular medicine. The current R&D initiatives include, but are not limited to, the following: Imaging In addi
Slide 13: Suite of Products
MINIMALINVESTOR PRESENTATION DESIGN 2016/2107 NOVEMBER ANNUAL REPORT 2019 TEMPLATE 13 SUITE OF PRODUCTS For personal use only REGULATORY CLEARED PRODUCTS: ▷ FerriScan® - (TGA, CE Mark, FDA); ▷ FerriSmart - (TGA, CE Mark, FDA); ▷ Cardiac T2* - (TGA, CE Mark, FDA); ▷ HepaFat-Scan® - (TGA, CE Mark, FDA
Slide 14: Iron Overload Market Fundamentals
1414 ANNUAL 2019 NOVEMBER REPORT TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 IRON OVERLOAD MARKET FUNDAMENTALS For personal use only Total Addressable Market • The World Health Organization estimates that over 330,000 affected infants are born annually (83% sickle cell disorders, 17% tha
Slide 15: Why Is Accurate Diagnosis of Iron Overload Important?
MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 ANNUAL REPORT NOVEMBER TEMPLATE 2019 1515 FDA mandates an approved ‘com- Inherited hemoglobin disorders, such as thalassemia and panion diagnostic’ to prescribe Ex- jade in Non-Transfusion Dependent For personal use only sickle cell disease, are now con
Slide 16: Metabolic Disease Market Fundamentals
16 16 ANNUAL REPORT NOVEMBER 2019 TEMPLATE MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 METABOLIC DISEASE MARKET FUNDAMENTALS For personal use only Total Addressable Market • Non-alcoholic Fatty Liver Disease (NAFLD) affects 10-30% of the global population of 7.6 billion people. • In the United Sta
Slide 17: Diagnosis and Therapy
INVESTOR MINIMAL PRESENTATION DESIGN 2016/2107 ANNUAL REPORT NOVEMBER 2019 TEMPLATE 17 Rising global obesity, caused by the consumption of high calorie and For personal use only nutrient poor diets, is increasing the rates of cardiovascular (heart) disease, diabetes, liver disease (NAFLD/NASH), and
Slide 18: Revenue Analysis by Region (FY 18/19)
18 18 ANNUAL NOVEMBER REPORT 2019 TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 REVENUE ANALYSIS BY REGION (FY 18/19) For personal use only
Slide 19: Investors Overview: Largest Shareholders
MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 ANNUAL REPORT NOVEMBER 2019 TEMPLATE 19 INVESTORS OVERVIEW LARGEST SHAREHOLDERS (AS OF 4 NOVEMBER 2019) Rank Name Units % of Units For personal use only 1 SOUTHAM INVESTMENTS 2003 PTY LTD 73,000,000 17.09 2 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 42,8
Slide 20: Contact details
For personal use only INVESTOR PRESENTATION Resonance Health (ASX: RHT) is an Australian healthcare company specialising in the development and delivery of non-invasive medical imaging software and analysis services. 141 Burswood Road, Burswood WA 6100 Telephone: +61 (0)8 9286 5300 Fax: +61 8 9286 5
Resonance Health — Investor Presentation (November 2019) on 6ix